Parthenolide and Its Analogues: A New Potential Strategy for the Treatment of Triple-Negative Breast Tumors

(E-pub Ahead of Print)

Author(s): Thaise Gonçalves Araújo*, Lara Vecchi, Paula Marynella Alves Pereira Lima, Everton Allan Ferreira, Igor Moreira Campos, Douglas Cardoso Brandão, Gabriela Silva Guimarães, Matheus Alves Ribeiro, Ademar Alves da Silva Filho.

Journal Name: Current Medicinal Chemistry

Abstract:

Triple negative breast cancers (TNBC) are heterogeneous and aggressive pathologies, with distinct morphological and clinical characteristics associated with their genetic diversity, epigenetics, transcriptional changes and aberrant molecular patterns. Treatment with anti-neoplastic drugs exerts systemic effects with low specificity, and incipient improvement in overall survival due to chemoresistance and recurrence. New alternatives for TNBC treatment are urgent and parthenolide or its analogues have been explored. Parthenolide is a sesquiterpene lactone with promising antitumor effects against TNBC cell lines. This review highlights the importance of parthenolide and its analogue drugs in TNBC treatment.

Keywords: Parthenolide, triple negative breast cancer, sesquiterpene lactones, nuclear factor-κB, heterogeneity, natural products.

Rights & PermissionsPrintExport Cite as

Article Details

(E-pub Ahead of Print)
DOI: 10.2174/0929867326666190816230121
Price: $95